Crizanlizumab-tmca (Adakveo)

Adakveo (crizanlizumab-tmca) is covered only to reduce vaso-occlusive crises in sickle cell disease patients aged ≥16 who have had ≥1 sickle cell–related crisis in the prior 12 months and meet hydroxyurea-related criteria (on hydroxyurea, intolerant/inadequate response, or not a candidate); off‑label uses and patients not meeting the age/prior‑crisis/hydroxyurea requirements are excluded. Coverage requires prescription by or consultation with a sickle‑cell specialist, documentation of diagnosis/age/prior crisis/hydroxyurea status, administration per FDA dosing (5 mg/kg IV Week 0, Week 2, then every 4 weeks), is authorized for 12 months, and reauthorization requires documented clinical benefit.

"Adakveo is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease."

Sign up to see full coverage criteria, indications, and limitations.